Correlation of IL-31 gene polymorphisms with susceptibility and clinical recurrence of bladder cancer
AbstractInterleukin-31 is a crucial cytokine triggering inflammation which could be one of the risk factors of tumors. However, data for correlation betweenIL-31 and tumors are limited. The purpose of our study was to discuss whether genetic polymorphisms ofIL-31 were associated with the susceptibility and clinical outcomes of bladder cancer. Our study enrolled 478 controls, 156 non-muscle-invasive bladder cancer (NMIBC) and 138 muscle-invasive bladder cancer (MIBC) patients. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was used for genotyping two single nucleotide polymorphisms (SNPs) ofIL-31 gene including rs7977932 and rs4758680. Our results showed that A allele and CA/AA genotypes of rs4758680 were associated with susceptibility to bladder cancer (P = 0.04, OR 1.32, 95% CI 1.01–1.72, andP = 0.02, OR 1.43, 95% CI 1.05–1.96, respectively), and G allele of rs7977932 might be a protect factor for tobacco smoking patients compared with non-smoking patients (P = 0.005, OR 0.42, 95% CI 0.23–0.76). Furthermore, CA/AA genotypes of rs4758680 might be the independent risk factors for the decreased recurrence-free survival of the patients with MIBC (P = 0.03, OR 2.02, 95% CI 1.06–3.85. Our data indicated that polymorphisms ofIL-31 are associated with bladder cancer, and rs4758680 could be an independent prediction for MIBC patients with a high risk of recurrence.
Authors: Siddiqui Z, Srivastava AN, Sankhwar SN, Dalela D, Singh V, Zaidi N, Fatima N, Bano I, Anjum S Abstract Purpose of the study: Therapy that targets cancer stem cells has the potential to eradicate cancer cells and prevent tumour recurrence. Therefore, we hypothesised the combined prognostic significance of stem cell markers CD44 (prevalent in basal layer of urothelial carcinoma) and Nanog (embryonic stem cell transcription factor) in bladder cancer.Material and Methods: CD44 and Nanog expression were determined by immunohistochemistry in 112 bladder cancer cases of which 79 were non-muscle invasive and 33 mu...
ConclusionsPembrolizumab provided durable antitumor activity in patients with locally advanced/metastatic UC that progressed after platinum-containing chemotherapy in the overall population and in the Japanese subgroup; safety profile was consistent with that previously observed for pembrolizumab.
Volume 47, Issue 1, December 2019, Page 4266-4272 .
Publication date: November 2019Source: European Urology Supplements, Volume 18, Issue 10Author(s): C. Van Der Fels, S. Palthe, M.C. Van Den Heuvel, I.J. De Jong
Publication date: November 2019Source: European Urology Supplements, Volume 18, Issue 10Author(s): R. Bientinesi, V. Di Paola, R. Manfredi, P. Bassi
ConclusionsA policy of selective histopathology after cholecystectomy is oncologically safe and reduces costs.
Condition: Bladder Cancer Intervention: Procedure: uretero ileal anastomosis in single trough Sponsor: Ain Shams University Completed
ConclusionsPositive findings in abdominopelvic washing cytology is rare. The majority of the positive cases were from müllerian origins, with ovary and uterus as the most common sites. Endometrial adenocarcinoma, endometrioid type and ovarian high-grade serous carcinoma were the most common tumor types. Knowing prior history of malignancy, morphologic comparison with concurrent surgical cases, and performing ancillary studies are keys to improve diagnostic accuracy of abdominopelvic washings.
SummaryA substantial increase in the number of elderly patients with muscle invasive bladder cancer (MIBC) is expected in upcoming years due to demographic changes and the peak incidence of bladder cancer in the 8th decade of life. The management of these patients is mainly driven by chronological age, co morbidities, tumor characteristics (unifocality, multifocality, concomitant carcinoma in situ, depth of invasion) and the presence of tumor-related symptoms (hematuria, pain, bladder dysfunction). A potential algorithm for the treatment of elderly patients with MIBC is presented. Ideally these pati ents ar...
ConclusionsPatient-related factors predicted 30 M whereas both patient-related and cancer-related factors predicted 30–90 M. This suggests that patient mix, i.e. patient- vs. cancer-related factors for 30 M and 30–90 M, should be taken into account if mortality rates are to be compared between hospitals.